Study of Healthy Aging and Physical function with Elamipretide (SHAPE)

The purpose of the study is to better understand the effects and potential benefits of elamipretide on skeletal muscle and cognitive function in older adults. Elamipretide, the study drug, has FDA accelerated approval as Forzinity™ only for use in the treatment of patients with Barth syndrome in the US weighing ≥ 30 kg

The study involves:
– Self daily injections for four weeks. You will receive training from study medical stuff
– Four in person study visits at FHCC over 8-10 weeks. Study visits are one-two hours long.
– Two follow-up phone calls from the study team.

The study will measure changes in cognitive function, mobility and muscle strength, and blood markers of health.

Study visits are held at the Fred Hutch Cancer Center’s Prevention Center (FHCC). located at Level E of the Robert M, Arnold Building.

Participants will receive $400 at the end of the study.

Participant Eligibility

• People aged 65-80 who are able to perform daily activities without assistance.
• Not participating in regular strenuous exercise training 2 or more times per week.
• Anyone taking supplements intended to increase muscle mass, energy or function, such as coenzyme Q10, creatine, or L-carnitine should be willing to stop taking them while they are on the study.

Contact

J.B. Ingram
206-387-7547